The National Tariff needs to take account of costs disproportionately borne by activity in a small number of providers. It separates payment for particular high-cost drugs, chemotherapy and high cost devices to achieve this, reimbursement through local negotiation, rather than through National Tariff prices.
Provision of nationally defined datasets is a condition of reimbursement and accurate, patient-level itemised high-cost drug expenditure is an immediate priority for NHS England.
· High-Cost Drugs List– see spreadsheet tab 13b in National Prices and Tariff workbook
· National Cancer Drugs Fund List
· Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund)